ASX ANNOUNCEMENT **28 AUGUST 2024**

First patient dosed in Phase 1/2 Clinical Trial of CDH17-directed CAR-T cell therapy

- **CHM CDH17 is a world leading CDH17-directed CAR-T cell therapy designed to treat patients with gastrointestinal (GI) cancers**
- **The first-in-human clinical trial of CHM CDH17 is recruiting subjects at US Cancer Centres with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours**
- **First patient dosed at Sarah Cannon Research Institute in Nashville, Tennessee**

Sydney, Australia, 28 August 2024: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce that the first patient enrolled in the first-in-human trial of CHM CDH17 has been dosed.

The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.

"Treating our first patient is a key milestone for Chimeric as we work to advance new medicines to improve the lives of patients living with cancer." said Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics.

Paul Hopper, Executive Chairman, reflected on this milestone: "This is a great moment for patients and the culmination of years of hard work by the Chimeric team."

The phase 1 portion of this study is expected to enrol 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.

CHM CDH17 is a 3rd generation, novel CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumours.

The clinical program for CHM CDH17 builds upon the preclinical studies published in the preeminent scientific journal, Nature Cancer in March 2022 by leading immunotherapy scientist Xianxin Hua, MD, PhD, and his team at the Abramson Family Cancer Research Institute at the University of Pennsylvania. These experiments demonstrated that CHM CDH17 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors
Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: + 61 498 966 180
E: RMcQualter@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au